New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma

Expert Review of Anticancer Therapy

Volumn 9, Issue 8, 2009, Pages 1159-1167

  Schmitt, Thomas ^a   Kasper, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Molecular targeted therapies; New treatment strategies; Positron emission tomography; Soft tissue sarcoma; Treatment standards

Indexed keywords

ARF PROTEIN; BENDAMUSTINE; BEVACIZUMAB; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IFOSFAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PIOGLITAZONE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; ROFECOXIB; SOMATOMEDIN RECEPTOR; THALIDOMIDE; TRABECTEDIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TROFOSFAMIDE; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE COURSE; DISTANT METASTASIS; DRUG TARGETING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LIVER DISEASE; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70350635631     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.64     Document Type: Review

References (93)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas: a pattern of care survey of the american college of surgeons. Ann. Surg. 205(4), 349-359 (1987). (Pubitemid 17059425)
3. Chbani L, Guillou L, Terrier P et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the french sarcoma group. Am. J. Clin. Pathol. 131(2), 222-227 (2009).
4. Toro JR, Travis LB, Wu HJ et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int. J. Cancer 119(12), 2922-2930 (2006).
5. Nakayama R, Nemoto T, Takahashi H et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod. Pathol. 20(7), 749-759 (2007) (Pubitemid 46933446)
6. Froehner M, Wirth MP. Etiologic factors in soft tissue sarcomas. Onkologie 24(2), 139-142 (2001). (Pubitemid 32449009)
7. Neuhaus SJ, Pinnock N, Giblin V et al. Treatment and outcome of radiation-induced soft-tissue sarcomas at a specialist institution. Eur. J Surg. Oncol. 35(6), 654-659 (2009).
8. Krishnan B, Khanna G, Clohisy D. Gene translocations in musculoskeletal neoplasms. Clin. Orthop. Relat. Res. 466(9), 2131-2146 (2008). •• Review on the genetic aberrations found in soft-tissue sarcoma (STS) and correlation with prognosis.
9. Gonin-Laurent N, Hadj-Hamou NS, Vogt N et al. RB1 and TP53 pathways in radiation-induced sarcomas. Oncogene 26(41), 6106-6112 (2007). (Pubitemid 47373799)
10. Tawbi H, Thomas D, Lucas DR et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 13(4), 459-466 (2008). (Pubitemid 351679927)
11. Dobashi Y, Suzuki S, Sugawara H, Ooi A. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum. Pathol. 38, 914-925 (2007). (Pubitemid 46726515)
12. de Alava E, Kawai A, Healey JH et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin. Oncol. 16(4), 1248-1255 (1998). (Pubitemid 28175736)
13. Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer SA. Synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin. Cancer Res. 14(24), 8191-8197 (2008).
14. Ladanyi M, Antonescu CR, Leung DH et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 62(1), 135-140 (2002). (Pubitemid 34073997)
15. Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J. Clin. Oncol. 22(20), 4040-4050 (2004). (Pubitemid 41185173)
16. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 13(Suppl. 2), 32-40 (2008)
17. Jaffe CC. Response assessment in clinical trials: implications for sarcoma clinical trial design. Oncologist 13(Suppl. 2), 14-18 (2008).
18. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 13(Suppl. 2), 4-7 (2008).
19. Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J Cancer 38(4), 543-549 (2002). (Pubitemid 34185394)
20. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur. J. Cancer 45(2), 228-247 (2009).
21. Yang JC, Chang AE, Baker AR et al. A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol. 16(1), 197-203 (1998). • Study highlighting the importance of adjuvant radiation therapy for high-grade extremity STS.
22. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19(Suppl. 2), 89-93 (2008).
23. Krempien R, Roeder F, Oertel S et al. Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 65(3), 773-779 (2006). (Pubitemid 43795839)
24. Pisters P. Staging and prognosis. In: American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Pollock RE (Ed.). Decker, Inc, Hamiliton, Ontario, Canada 80-88 (2002).
25. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 10(10), 833-841 (2005). (Pubitemid 43152701)
26. Grobmyer SR, Maki RG, Demetri GD et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann. Oncol. 15(11), 1667-1672 (2004).
27. Gortzak E, Azzarelli A, Buesa J et al. A randomised Phase II study on neoadjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur. J. Cancer 37(9), 1096-1103 (2001).
28. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113(3), 573-581 (2008). •• Meta-analysis reflecting the ongoing debate on the benefit of adjuvant chemotherapy.
29. Le Cesne A, Van Glabbeke M, Woll PJ et al. The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: pooled analysis of the two STBSG-EORTC Phase III clinical trials. J. Clin. Oncol. 26(15s), 559s (2008).
30. Jelic S, Kovcin V, Milanovic N et al. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur. J Cancer 33(2), 220-225 (1997). (Pubitemid 27117718)
31. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a Phase II study. J. Clin. Oncol. 16(4), 1438-1443 (1998). (Pubitemid 28175763)
32. Bui NB, Demaille MC, Chevreau C et al. qMAID vs MAID + 25 % in adults with advanced soft tissue sarcoma (STS): first results of a randomized study of the FNCLCC sarcoma Group. Proc. Am. Soc. Clin. Oncol. 17, 517a (1998).
33. Nielsen OS, Judson I, van Hoesel Q et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas: a multicentre Phase II study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 36(1), 61-67 (2000). (Pubitemid 30035345)
34. Frustaci S, Buonadonna A, Romanini A et al. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas: a study of the Italian group on rare tumors. Tumori 85(4), 229-233 (1999). (Pubitemid 29482206)
35. Demetri GD. Major developments in the understanding and treatment of soft-tissue sarcomas in adults. Curr. Opin. Oncol. 10(4), 343-347 (1998).
36. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M. Sarcoma disease site group of cancer care Ontario's program in evidence-based care dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer 112(6), 1197-1205 (2008).
37. Kasper B, Dietrich S, Mechtersheimer G, Ho AD, Egerer G. Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients. Oncology 73(1-2), 58-64 (2007).
38. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. 20(12), 2824-2831 (2002). (Pubitemid 34651511)
39. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II trial. Gynecol. Oncol. 109(3), 329-334 (2008). (Pubitemid 351754961)
40. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26(32), 5269-5274 (2008).
41. Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 44(16), 2433-2436 (2008). (Pubitemid 46486707)
42. Maki RG, Wathen JK, Patel SR et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 25(19), 2755-2763 (2007).
43. Duffaud F, Bui BN, Penel N et al. A FNCLCC french sarcoma group-GETO multicenter randomized Phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J. Clin. Oncol. 26(15s), (2008).
44. Hartmann JT, Mayer F, Schleicher J et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter Phase II study of the german sarcoma group. Cancer 110(4), 861-866 (2007). (Pubitemid 47257665)
45. Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res. 23(2C), 1899-1901 (2003).
46. Kasper B, Ho AD, Egerer G. A new therapeutic approach in patients with advanced sarcoma. Int. J. Clin. Oncol. 10(6), 438-440 (2005). (Pubitemid 41821530)
47. Verweij J. Ecteinascidin-743 (ET-743): Early test or effective treatment in soft tissue sarcomas? J. Clin. Oncol. 23(24), 5420-5423 (2005). (Pubitemid 46300124)
48. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007). (Pubitemid 46995623)
49. Blay JY, von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin. Cancer Res. 14(20), 6656-6662 (2008).
50. Sessa C, Perotti A, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur. J. Cancer 45(7), 1153-1161 (2009).
51. Leahy M, Ray-Coquard I, Verweij J et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a Phase II study from the european organisation for research and treatment of cancer soft tissue and bone sarcoma group. Eur. J. Cancer 43(2), 308-315 (2007). (Pubitemid 46138040)
52. Yoon SS, Segal NH, Park PJ et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J. Surg. Res. 135(2), 282-290 (2006).
53. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann. Oncol. 15(8), 1261-1266 (2004). (Pubitemid 39199315)
54. Yi-Shin Kuo D, Timmins P, Blank SV et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol. Oncol. 100(1), 160-165 (2006). (Pubitemid 41815067)
55. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J. Clin. Oncol. 23(28), 7135-7142 (2005). (Pubitemid 46260301)
56. Maki RG, Keohan ML, Undevia M et al. Updated results of a Phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study 7060. J. Clin. Oncol. 26(15s), 560s (2008).
57. Keohan ML, Morgan JA, D'Adamo DR et al. Continuous daily dosing (CCD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a Phase II trial. J. Clin. Oncol. 26(15s), 501s (2008).
58. Sleijfer S, Papai Z, Le Cesne A et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS). EORTC 62043. Proc. Am. Soc. Clin. Oncol. 25, 18s (2007).
59. Ren W, Korchin B, Zhu QS et al. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin. Cancer Res. 14(9), 2785-2795 (2008).
60. Keizman D, Issakov J, Meller I et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J. Neurooncol. DOI 10.1007/s11060-009-9862-z (2009) (Epub ahead of print).
61. Ray-Coquard I, Le Cesne A, Whelan JS et al. A Phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 13(4), 467-473 (2008). (Pubitemid 351679928)
62. Ren W, Korchin B, Lahat G et al. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin. Cancer Res. 14(17), 5466-5475 (2008).
63. Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYTSSX)-positive cases. Am. J. Surg. Pathol. 26(11), 1434-1440 (2002). (Pubitemid 35239419)
64. Kaseta MK, Khaldi L, Gomatos IP et al. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J. Surg. Oncol. 97(3), 259-266 (2008). (Pubitemid 351312167)
65. Joyner DE, Albritton KH, Bastar JD, Randall RL. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J. Orthop. Res. 24(6), 474-480 (2006).
66. Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med. 13(6), 748-753 (2007). (Pubitemid 46889749)
67. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 12(8), 1007-1018 (2007).
68. Chawla S, Tolcher A, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of Phase II trial. Proc. Am. Soc. Clin. Oncol. 25, 18s (2007).
69. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin. Cancer Res. 15(2), 589-596 (2009).
70. Misset JL, Gamelin E, Campone M et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann. Oncol. 15(7), 1123-1129 (2004). (Pubitemid 39089790)
71. Hartmann JT, Bauer S, Schaedel S et al. A non-comparative Phase II study of pemetrexed in patients with pretreated soft tissue sarcoma: german sarcoma group/ AIO 005. J. Clin. Oncol. 26(15s) (2008).
72. Morris DG, Bramwell VH, Turcotte R et al. A Phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006, 64374 (2006). (Pubitemid 44526147)
73. D'Adamo DR, Scheu K, Singer S et al. A Phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol. 24, 18s (2006).
74. Kutko MC, Glick RD, Butler LM et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin. Cancer Res. 9(15), 5749-5755 (2003).
75. Yamamoto S, Tanaka K, Sakimura R et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 28(3A), 1585-1591 (2008). (Pubitemid 351892934)
76. Kelly WK, O'Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17), 3923-3931 (2005).
77. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J. Pathol. 217(4), 469-482 (2009).
78. Olmos D, Okuno S, Schuetze SM et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. J. Clin. Oncol. 26(15s) (2008) (Abstract 10501).
79. Benz MR, Evilevitch V, Allen-Auerbach MS et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors, J. Nucl. Med. 49(7), 1038-1046 (2008). (Pubitemid 351948010)
80. Folpe AL, Lyles RH, Sprouse JT et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin. Cancer Res. 6(4), 1279-1287 (2000).
81. Völker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J. Clin. Oncol. 25(34), 5435-5441 (2007). (Pubitemid 350232220)
82. Evilevitch V, Weber WA, Tap WD et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin. Cancer Res. 14(3), 715-720 (2008). •• Highlights the usefulness of [18F] fluorodeoxyglucose-PET in assessing tumor response to chemotherapy. (Pubitemid 351231152)
83. Schuetze SM, Rubin BP, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103(2), 339-348 (2005). (Pubitemid 40129294)
84. Lisle JW, Eary JF, O'Sullivan J, Conrad EU. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin. Orthop. Relat. Res. 467(6), 1605-1611 (2009).
85. Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur. J. Nucl. Med. Mol. Imaging 31, 189-195 (2004). (Pubitemid 38173693)
86. Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur. J. Nucl. Med. Mol. Imaging 33(11), 1290-1295 (2006). (Pubitemid 44630784)
87. Kasper B, Dietrich S, Dimitrakopoulou- Strauss A et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography, Onkologie 31(3), 107-112 (2008). (Pubitemid 351348089)
88. Buck AK, Herrmann K, Büschenfelde CM et al. Imaging bone and soft tissue tumors with the proliferation marker [18F] fluorodeoxythymidine. Clin. Cancer Res. 14(10), 2970-2977 (2008).
89. Baur A, Stäbler A, Wendtner CM et al. MR-imaging changes of musculoskeletal soft-tissue sarcomas associated with neoadjuvant chemotherapy and hyperthermia, Int. J. Hyperthermia 19(4), 391-401 (2003). (Pubitemid 36798299)
90. Dudeck O, Zeile M, Pink D et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J. Magn. Reson. Imaging 27(5), 1109-1113 (2008). • Study focusing on the use of special MRI techniques to predict tumor response to chemotherapy. (Pubitemid 351614624)
91. Stacchiotti S, Collini P, Messina A et al. High-grade soft-tissue sarcomas: tumor response assessmen - pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251(2), 447-456 (2009).
92. Song T, Shen J, Liang BL, Mai WW, Li Y, Guo HC. Retroperitoneal liposarcoma: MR characteristics and pathological correlative analysis. Abdom. Imaging 32(5), 668-674 (2007). (Pubitemid 47594247)
93. Lahat G, Madewell JE, Anaya DA et al. Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes. Cancer 115(5), 1081-1090 (2009).